Answers are grounded in this paper and cite their sources.
Along with scientific and regulatory issues, the translation of cell and tissue therapies in the routine clinical practice needs to address standardization and cost-effectiveness through the definition of suitable manufacturing paradigms.
No takes yet. Share an insight, caveat, or question.
Martín et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: